At Boehringer Ingelheim, we are providing new hope for patients by taking cancer on. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
1. Torre LA, et al. CA Cancer J Clin 2015;65(2):87–108.
2. Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr/Pages/burden_sel.aspx (Accessed: 3 July 2017).
3. Schvartsman G, et al. Ther Adv Med Oncol 2016;8(6):460–73.
As monotherapy, it is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase inhibitor (TKI) naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) and treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.1
1. Afatinib (Giotrif®) Prescribing Information, July 24, 2017
Production date: Nov 2018